Eszopiclone versus zopiclone in the treatment of insomnia

Luciano Ribeiro Pinto Jr, Lia Rita Azeredo Bittencourt, Erika Cristine Treptow, Luciano Rotella Braga, Sergio Tufik, Luciano Ribeiro Pinto Jr, Lia Rita Azeredo Bittencourt, Erika Cristine Treptow, Luciano Rotella Braga, Sergio Tufik

Abstract

Objective: To determine the therapeutic effects of two selective GABA-A agonists, zopiclone and eszopiclone, in the treatment of insomnia.

Methods: This study comprised a phase III, single-center, randomized, double-blind, double-dummy, parallel-group, non-inferiority trial. Patients were randomized to receive zopiclone 7.5 mg or eszopiclone 3 mg, both orally, for four weeks. In total, 199 patients were evaluated during two visits and then followed for at least six weeks. The primary endpoint was the Insomnia Severity Index after four weeks of treatment. Secondary endpoints were obtained through polysomnography data, including total sleep time, sleep latency and sleep efficiency. The frequency of adverse events was also analyzed. ClinicalTrials.gov: NCT01100164.

Results: The primary efficacy analysis demonstrated the non-inferiority of eszopiclone over zopiclone. Analysis of objective parameters assessed by polysomnography showed that eszopiclone increased total sleep time and also improved sleep efficiency. The safety profile of both study treatments was similar and the most common events reported in both groups were dysgeusia, headache, dizziness, irritability and nausea. Adverse events were observed in 223 patients, 109 (85.2%) in the eszopiclone group and 114 (87.7%) in the zopiclone group.

Conclusion: Based on the Insomnia Severity Index at the end of four weeks of treatment, eszopiclone demonstrated efficacy comparable to that of zopiclone in the treatment of insomnia, increasing total sleep time as well as sleep efficiency according to polysomnography.

References

    1. Castro LS, Poyares D, Leger D, Bittencourt L, Tufik S. Objective prevalence of insomnia in the Sao Paulo, Brazil epidemiologic sleep study. Ann Neurol. 2013;74((4)):537–46.
    1. Fava GA, Grandi S, Canestrari R, Molnar G. Prodromal symptoms in primary major depressive disorder. J Affect Disord. 1990;19((2)):149–52.
    1. McCall WV. A psychiatric perspective on insomnia. J Clin Psychiatry. 2001;62((Suppl 10)):27–32.
    1. National Sleep Foundation. Los Angeles: 1991. Sleep in America: A survey of US adults. A report prepared by the Gallup Organization for the National Sleep Foundation.
    1. Roth T. Insomnia: Definition, Prevalence, Etiology, and Consequences. J Clin Sleep Med. 2007 Aug 15;3((5 Suppl)):S7–S10.
    1. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention. JAMA. 1989;262((11)):1479–84.
    1. Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. The American journal of managed care. 2006;12((Suppl 8)):S221–9.
    1. Pinto Jr LR, Alves RC, Caixeta E, Fontenelle JA, Bacellar A, Poyares D, et al. New guidelines for diagnosis and treatment of insomnia. Arq Neuropsiquiatr. 2010;68((10)):666–75.
    1. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26((4)):261–82.
    1. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343.
    1. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6((6)):487–95.
    1. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26((7)):793–9.
    1. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007;30((8)):959–68.
    1. Boyle J, Groeger JA, Paska W, Groeger JA, Paska W, Cooper JA, Rockett C, Jones S, Gandhi P, et al. A method to assess the dissipation of the [corrected] residual effects of [corrected] hypnotics: eszopiclone versus zopiclone. J Clin Psychopharmacol. 2012;32((5)):704–9.
    1. American Psychological Association. Diagnostic and statistical manual of mental disorders. Washington, D.C.: 1994. (4th ed.)
    1. American Academy of Sleep Medicine AASM. The AASM Manual for the Scoring of Sleep and Associated Events: American Academy of Sleep Medicine. 2005.
    1. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2((4)):297–307.
    1. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28((2)):193–213.
    1. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006;295((24)):2851–8.
    1. Sukys-Claudino L, Moraes WAS, Tufik S, Poyares D. Novos sedativos hipnóticos. Rev Bras Psiquiatr. 2010;32((3)):288–93.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner